Etomerzol for Health & Longevity
Evidence Review created on 10/29/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: Ethomersol, Ethomerzol, Etomersol, Etomerzole, Ethomersole, Tomerzol, Tomersol, 5-ethoxy-2-ethylthiobenzimidazole, 5-ethoxy-2-ethylmercaptobenzimidazole, 5-EEMBI, 5-ETOB
Motivation
Etomerzol (ethomersol) is a synthetic compound created in the late Soviet era as a water-soluble relative of bemitil, a drug once given to cosmonauts, soldiers and athletes to sustain hard physical work. It was designed to raise the body’s tolerance of heavy exertion, oxygen shortage and toxic stress without acting like a classic stimulant. Its proposed action centers on helping cells keep producing energy when oxygen runs short.
Interest in etomerzol comes from military medicine. Research groups in Russia and Ukraine studied it in animal models of oxygen shortage and poisoning, and in a small number of healthy volunteers and poisoned patients in the early 1990s. Clinical work largely stopped after the Soviet Union dissolved, and no approved product exists. It now circulates mainly as a research chemical, which has drawn attention from people interested in physical resilience and recovery.
This review examines what is known about etomerzol’s mode of action, the human and animal evidence behind its proposed benefits, its known and suspected harms, and the practical questions of dosing, sourcing and monitoring, from the perspective of health-focused adults weighing resilience-oriented interventions.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
The items below discuss etomerzol by name, from a class-level review to the primary clinical, experimental and toxicity work.
-
The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance - Oliynyk & Oh, 2012
The only English review with a dedicated etomerzol section: its origin as an injectable bemitil analog, mechanism, interrupted 1990–91 clinical studies and their injection-site complications, within the actoprotector (synthetic endurance-enhancing agent) class.
-
Применение актопротекторов в комплексном лечении острых экзогенных отравлений карбофосом, дихлорэтаном и этиленгликолем - Aksenov, 1996
Russian dissertation summary from the Military Medical Academy, home of the actoprotector program, holding all published human data: volunteer tolerability and endurance, pharmacokinetics (how the body absorbs and clears it) and a small patient trial.
-
Нейропротекторная активность 5-этокси-2-этилтиобензимидазола (этомерзола) и 2-этилтиобензимидазола (бемитила) на модели окклюзии среднемозговой артерии - Zavarina et al., 2023
The most recent primary study (Russian), comparing etomerzol with bemitil and dimethyl fumarate (a multiple-sclerosis drug) in a rat stroke model; shows research continuing at an independent St. Petersburg pharmaceutical university.
-
Влияние томерзола (5-этоб, этомерзола) на картину крови и морфологическое состояние органов интактных крыс - Pitkevich, 2012
Belarusian conference report and the only repeated-dose toxicity study found: four weeks of daily injections in rats damaged liver and kidney, and the author judged 7–10 days the safe duration.
Only four items are listed: the remaining etomerzol literature consists of short animal studies or further work from the Military Medical Academy, which is already represented.
No etomerzol content was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io; the compound has almost no English-language literature and has not entered mainstream longevity discussion.
Grokipedia
No Grokipedia article on etomerzol exists.
Examine
No Examine article on etomerzol exists. Examine.com does not typically cover investigational or unapproved drugs.
ConsumerLab
No ConsumerLab article on etomerzol exists. ConsumerLab does not typically cover investigational or unapproved drugs.
Systematic Reviews
No systematic reviews or meta-analyses for Etomerzol were found on PubMed as of October 25, 2026.
Neither the claimed benefits nor the principal risks (injection-site injury, organ toxicity with repeated dosing) are covered by any systematic review or meta-analysis.
Mechanism of Action
Etomerzol is 5-ethoxy-2-ethylthiobenzimidazole hydrochloride, a benzimidazole (a two-ring nitrogen compound resembling the purine building blocks of genetic material) closely related to bemitil, according to a review (Oliynyk 2012). No receptor target has been identified, and three explanations compete:
- Protein-synthesis activation: the class is proposed to boost production of RNA (the molecule carrying genetic instructions to protein factories), mitochondrial (cellular power-plant) enzymes and gluconeogenesis (glucose rebuilding from lactate) enzymes, sustaining ATP (the cell’s energy currency) under low oxygen; this rests mainly on bemitil, whose effects vanish when protein synthesis is blocked, according to a review (Oliynyk 2012).
- Antioxidant action: etomerzol reduced lipid peroxidation (oxidative damage to membrane fats) in rat brain, liver and test-tube systems (Mironova 2003), yet showed no direct free-radical scavenging (neutralizing reactive oxygen molecules) in another rat study (Plotnikov 1992).
- Vascular and blood effects: in animals it blocked voltage-dependent calcium channels (pores through which calcium triggers vessel constriction), inhibited platelet clumping (Plotnikova 1992) and lowered hemoglobin’s oxygen affinity, easing oxygen release to tissue (Plotnikova 1991).
Pharmacology: after intramuscular (into-muscle) injection in eight healthy people, the elimination half-life (time for blood levels to halve) was about 2.1 hours (Aksenov 1996). In rats it distributes into liver, brain, heart, kidney, lung and fat (Sergeeva 2008). Its metabolizing enzymes are unstudied; bemitil is excreted as conjugates (water-soluble attachments) (Belinskaia 2021).
Historical Context & Evolution
Etomerzol grew out of the Soviet actoprotector program at the Military Medical Academy in Leningrad, which in the 1970s produced bemitil for cosmonauts, soldiers and athletes, per a review (Oliynyk 2012). Bemitil dissolves poorly in water and could not be injected, so in the late 1980s etomerzol was developed as a water-soluble analog for intravenous (into-vein) and intramuscular use in military toxicology, surgery and resuscitation. Accounts of its origin differ: the review credits Ukrainian manufacturing in Kharkiv (Oliynyk 2012), while a 1996 dissertation names the Institute of Organic Chemistry of the Ukrainian Academy of Sciences (Aksenov 1996).
Its original intended use was acute: speeding recovery after poisoning, blood loss, brain injury and oxygen shortage. Clinical testing included healthy volunteers and patients with insecticide poisoning; the review dates the patient studies to 1990–91. The dissertation reported good tolerability and faster recovery (Aksenov 1996), whereas the later review reported that the acidic solution caused frequent injection-site complications (Oliynyk 2012). Clinical work reportedly stopped after 1991, though a 2012 Belarusian report describes completed clinical trials and an injectable ampoule form (Pitkevich 2012); later work is animal-only, most recently a 2023 rat stroke study (Zavarina 2023).
Its relevance to health optimization rests on the actoprotector concept itself — raising tolerance of physical load, heat and oxygen shortage — and on athletes’ use of its oral relative bemitil. No study has examined etomerzol for aging, chronic-disease prevention or long-term use; its standing reflects halted development, not a negative trial.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: the only human efficacy data are one small single-blind patient trial (patients unaware of their group) and one volunteer study, both from a single research group and never replicated independently.
Medium 🟩 🟩
Faster Recovery After Organophosphate Poisoning ⭕️ Not Central to Health & Longevity
In a single-blind study of moderate or severe malathion (organophosphate insecticide) poisoning, intramuscular etomerzol added to standard care sped recovery of grip strength, breath-holding, cardiovascular indices, liver enzymes, creatinine (a kidney-function marker) and mood scores (Aksenov 1996). A review reports that 1990–91 organophosphate-poisoning studies at the same academy were generally positive (Oliynyk 2012). The institution behind the actoprotector program ran the study, only 29 patients were analyzed in groups, and allocation was not described. It bears on acute toxicology recovery, not aging or healthy-adult performance.
Magnitude: Day-7 hand-grip scores were 16.3 percentage points higher than standard care alone in moderate poisoning (72.7% vs 56.4%) and 30.8 points higher in severe poisoning (76.7% vs 45.9%); function normalized by day 7 vs day 11 (moderate) and day 10 vs day 16 (severe); p<0.05 (chance explanation below 5%), no confidence interval (range of plausible true values) reported (Aksenov 1996).
Low 🟩
Greater Endurance During Prolonged Physical Work
Healthy volunteers given etomerzol showed better static and dynamic muscular endurance and cardiovascular tolerance during 6- and 24-hour physical loads, exceeding bemitil at 24 hours (Aksenov 1996). Control, randomization and participant numbers are unreported and the data were never peer-reviewed; class reviews rely on bemitil trials (Oliynyk 2012).
Magnitude: Direction only: endurance and recovery improved during 6- and 24-hour exertion; the source reports no outcome figure.
Speculative 🟨
Protection After Brain Ischemia or Injury ⭕️ Not Central to Health & Longevity
In rats, etomerzol reduced brain swelling and neurological deficits after acute or chronic ischemia (blocked blood flow) or head trauma (Vaizova 1994, Zarubina 2005, Zavarina 2023). Relevant to stroke and trauma care; animal data only.
Tolerance of Oxygen Shortage
Etomerzol protected animals during acute low-pressure hypoxia (oxygen shortage) and recovery (Kosolapov 1996) and lowered hemoglobin’s oxygen affinity (Plotnikova 1991). Basis is animal data only.
Reduced Oxidative Damage
Etomerzol lowered lipid-peroxidation products and raised glutathione (the main cellular antioxidant) and antioxidant-enzyme activity in hypoxic rat brain and liver (Mironova 2003). These are unvalidated animal biomarkers; no human data exist.
Liver Regeneration ⭕️ Not Central to Health & Longevity
After partial liver removal in rats, etomerzol sped liver regrowth and function recovery (Gaivoronskaia 2000), an effect lost after thymus removal (Okovity 2002). It bears on recovery from liver surgery; basis is animal data only.
Circulatory Support in Hemorrhagic Shock ⭕️ Not Central to Health & Longevity
In cats with hemorrhagic shock (circulatory collapse from blood loss), etomerzol added to saline infusion improved circulation (Udovichenko 1991). Single animal study; relevant to emergency care only.
Immune Cell Activation
In mice, etomerzol increased macrophage (scavenger immune cell) engulfing activity more than bemitil (Ratnikov 1991) and in stressed rats boosted antibody-forming cells (Okovity 2002). Basis is animal data only.
Benefit-Modifying Factors
- Genetic polymorphisms: No study has examined genetic modifiers. If etomerzol shares bemitil’s conjugation pathways (Belinskaia 2021), variants in GST (glutathione S-transferase, a detoxifying enzyme) genes such as the GSTM1 deletion (a common gene loss) could alter exposure; this is untested.
- Baseline hypoxia tolerance: Etomerzol helped rats with both high and low innate tolerance of oxygen shortage after brain trauma (Zarubina 2005); a review describes actoprotector effects as strongest with low or average resistance to extreme conditions and nearly absent with high resistance (Oliynyk 2012).
- Baseline biomarkers: No human study links laboratory values to response. Patient and animal benefits appeared when oxidative markers and liver enzymes were already disturbed (Aksenov 1996); effects with normal values are unknown.
- Sex: The poisoning study enrolled 20 men and 14 women but reported no sex-specific results (Aksenov 1996); no other human data exist.
- Pre-existing conditions: All human benefit signals come from acute poisoning or extreme exertion, and animal signals from ischemia (blocked blood flow), trauma and shock. Whether unstressed healthy adults gain anything is untested.
- Age: Poisoned patients averaged 45 years (Aksenov 1996); no data exist for older adults, whose slower drug clearance could change both effect and exposure.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: human safety data are uncontrolled observations from two early-1990s clinical studies by one research group.
Medium 🟥 🟥
No risk reaches Medium: no human study with a comparison group has reported adverse-event rates for etomerzol.
Low 🟥
Injection-Site Injury ⚠️ Conflicted
The acidic injectable solution (pH about 3) caused phlebitis (vein inflammation) after intravenous use and painful aseptic (non-infectious) inflammation, sometimes necrosis (tissue death), after intramuscular use in 1990–91 patients, per a review (Oliynyk 2012). Volunteers reported only moderate injection pain (Aksenov 1996). Net reading: injury is likely; severity uncertain.
Magnitude: Direction only: complications followed injection of the pH ~3 solution, with phlebitis after intravenous use and aseptic inflammation, sometimes necrosis, after intramuscular use; the literature reports no outcome figure, no event rate and no comparison group.
Digestive Upset and Overstimulation ⚠️ Conflicted
For the oral relative bemitil, a review lists nausea, stomach discomfort, irritability, shortened sleep, headache and facial flushing (Oliynyk 2012); this is indirect, analog evidence. Etomerzol volunteers showed no adverse psychological shifts (Aksenov 1996). Net reading: plausible but unconfirmed.
Magnitude: Direction only: for bemitil, nausea is described as seldom and occurring mainly on an empty stomach; the literature reports no outcome figure, and the etomerzol volunteer study reports no rates and no comparison group.
Speculative 🟨
Liver and Kidney Damage With Repeated Dosing
Daily intramuscular etomerzol (40 mg/kg) caused progressive liver-cell and kidney-tubule degeneration in rats from week two, with none after one week (Pitkevich 2012). Basis is a single animal study.
Platelet Count Swings
Rats given daily injections developed raised platelet counts at two weeks, then low counts, plus a transient hemoglobin rise (Pitkevich 2012). Animal data only; human blood counts were never reported.
Bleeding Tendency
Etomerzol inhibited platelet aggregation (clumping) triggered by several agents in rats (Plotnikova 1992), which could add to bleeding risk, especially with anticoagulant (clot-slowing) drugs. Mechanistic and animal basis only.
Low Blood Pressure
Etomerzol relaxed vessels by blocking calcium channels in rats (Plotnikova 1992). Volunteers showed no relevant cardiovascular change (Aksenov 1996); the concern is mechanistic.
Risk-Modifying Factors
- Genetic polymorphisms: None studied. Variants in GST or UGT (UDP-glucuronosyltransferase, an enzyme that attaches water-soluble groups) genes could change clearance if etomerzol follows bemitil’s conjugation pathways (Belinskaia 2021); this is theoretical.
- Baseline biomarkers: Elevated liver enzymes, reduced kidney function or low platelet counts at baseline would compound the liver, kidney and platelet changes seen in rats (Pitkevich 2012); no human threshold data exist.
- Sex: No sex-specific safety data exist; the poisoning study did not report adverse events by sex (Aksenov 1996).
- Pre-existing conditions: Acute poisoning lengthened human half-life from 2.1 to 7.8–9.0 hours (Aksenov 1996), suggesting accumulation with liver or kidney impairment. Bleeding disorders and low blood pressure raise theoretical concern from platelet and vessel effects.
- Age: Older adults generally clear drugs more slowly through liver and kidneys; with no etomerzol data in this group, accumulation and injection-site tolerance are unknown.
- Route of administration: A review ties injection-site injury to the acidic injectable form (Oliynyk 2012); oral use avoids it but has no human safety data.
Key Interactions & Contraindications
Documented interactions:
- Organophosphate insecticide poisoning (malathion): In humans, poisoning slowed absorption and elimination, lengthening half-life from 2.1 to 7.8–9.0 hours (Aksenov 1996); consequence: accumulation. The source recommends once-daily dosing for the first 3 days in severe poisoning.
- Standard organophosphate-poisoning care: Given alongside it in 15 patients, etomerzol showed no reported interaction (Aksenov 1996); no formal interaction measurement was made.
Theoretical interactions (inferred from mechanism, not studied in humans):
- Anticoagulants and antiplatelet drugs (drugs that slow clotting: warfarin, apixaban, clopidogrel, aspirin): additive platelet inhibition, inferred from rat data (Plotnikova 1992); consequence: increased bleeding risk. Mitigation: watching for bruising or bleeding; INR (clotting-time ratio) checks with warfarin.
- NSAIDs (nonsteroidal anti-inflammatory pain relievers: ibuprofen, naproxen): additive antiplatelet effect from etomerzol’s platelet inhibition; consequence: gastrointestinal or other bleeding. Mitigation: acetaminophen, which lacks antiplatelet action, for pain during exposure.
- Calcium channel blockers (vessel-relaxing blood-pressure drugs: amlodipine, nifedipine, verapamil) and other antihypertensives (blood-pressure-lowering drugs: lisinopril, losartan): additive vessel relaxation from calcium-channel blockade; consequence: low blood pressure, dizziness. Mitigation: home blood-pressure checks.
- Narrow-margin drugs cleared by CYP1A (a cytochrome P450 liver drug-clearing enzyme family: theophylline, clozapine, warfarin): bemitil induced mainly CYP1A in rats (Gulyaeva 2009); etomerzol shortened hexobarbital (test sedative) sleep in rats after liver surgery (Gaivoronskaia 2000); consequence: lower drug levels. Mitigation: drug-level monitoring.
- Glucose-lowering drugs (insulin; sulfonylureas, which push the pancreas to release insulin, e.g., glimepiride): additive glucose lowering, inferred from bemitil’s slight lowering of blood glucose under heavy load and its hypoglycemia (low blood sugar) contraindication in a review (Oliynyk 2012); consequence: hypoglycemia. Mitigation: glucose monitoring.
- Barbiturates (sedative drugs: phenobarbital, butalbital): altered barbiturate clearance, inferred from shortened hexobarbital sleep in etomerzol-treated rats (Gaivoronskaia 2000) and bemitil’s barbiturate contraindication in a review (Oliynyk 2012); consequence: unpredictable sedation. Mitigation: not combining them.
- Stimulants (caffeine, modafinil): additive arousal, inferred from bemitil’s psychoactivation (mental activation) reported in a review (Oliynyk 2012); consequence: irritability, disrupted sleep. Mitigation: limiting caffeine after midday.
- Supplements with antiplatelet effects (fish oil, ginkgo, high-dose vitamin E, garlic): additive platelet inhibition; consequence: bleeding risk. Mitigation: pausing them during a course.
- Supplements that lower blood pressure (magnesium, beetroot nitrate, L-citrulline): additive vessel relaxation from calcium-channel blockade; consequence: hypotension (low blood pressure), dizziness. Mitigation: blood-pressure checks.
- Other actoprotectors and antihypoxants (oxygen-shortage protectors: bemitil, bromantane, meldonium): overlapping metabolic action; consequence: unpredictable additive stimulation and liver load. Mitigation: not combining courses.
Populations who should avoid Etomerzol:
- Pregnancy and breastfeeding: no reproductive or developmental data exist; inferred from this absence and from organ toxicity in rats (Pitkevich 2012); no human data.
- Liver or kidney impairment: inferred from liver and kidney degeneration in rats after two weeks (Pitkevich 2012) and slowed human elimination during poisoning (Aksenov 1996).
- Bleeding disorders, thrombocytopenia (low platelet count) or upcoming surgery: inferred from platelet inhibition and platelet-count swings in rats (Plotnikova 1992, Pitkevich 2012); no human data.
- People prone to hypoglycemia: inferred from bemitil’s blood-glucose lowering under heavy load and its contraindication listed in a review (Oliynyk 2012); not studied for etomerzol.
- Children and adolescents: inferred from the absence of any pediatric pharmacokinetic or safety data and from organ toxicity in rats (Pitkevich 2012); no human data.
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Limiting course length to 7–10 days: rats showed no organ changes after one week but progressive liver and kidney damage from week two; the author judged 7–10 days safe (Pitkevich 2012). Mitigates cumulative organ toxicity.
- Liver and kidney panel around each course: ALT (alanine aminotransferase, a liver-injury enzyme), AST (aspartate aminotransferase, a liver and muscle enzyme), bilirubin and creatinine detect rat-type organ damage; stopping if ALT exceeds 3× normal.
- Platelet count checks: a complete blood count at baseline and day 7 detects the platelet swings seen in rats (Pitkevich 2012); stopping if platelets fall below 100 ×10⁹/L limits bleeding risk.
- No injection of research-grade material: the acidic injectable caused phlebitis and necrosis, per a review (Oliynyk 2012); research powders are not sterile, adding infection risk to local tissue injury.
- Pausing antiplatelet supplements: stopping fish oil, ginkgo or high-dose vitamin E during a course reduces additive bleeding risk from etomerzol’s platelet inhibition (Plotnikova 1992).
- Home blood-pressure readings: daily readings during the first 3 days detect hypotension from calcium-channel blockade, especially alongside blood-pressure drugs; stopping if systolic (upper-number) pressure falls below 90 mmHg or dizziness occurs.
- Morning dosing: limits the sleep disruption that a review reports for the related compound bemitil (Oliynyk 2012).
Therapeutic Protocol
Parameters other than doses (timing, course length, dose splitting) reflect common practice unless cited.
- No longevity protocol: no practitioner, guideline or trial defines etomerzol use for health or longevity; the only human regimen comes from poisoning and volunteer studies (Aksenov 1996).
- Clinical regimen (injection): 2 mL of 4% solution (80 mg) intramuscularly once or twice daily, started on day 1–2 of poisoning (Aksenov 1996); developed by Sosyukin and Smirnov’s group at the Military Medical Academy.
- Severe-illness adjustment: once daily for the first 3 days, then twice daily for 7–10 days, because elimination slows markedly (Aksenov 1996).
- Oral use: no human oral dose has been studied; rats received 50 mg/kg orally for 10 days (Vaizova 1994). Rat doses do not translate directly to humans.
- Competing approaches: a pharmacology review treats etomerzol as an investigational injectable for acute care (Oliynyk 2012); performance-oriented users treat it as an oral research chemical without a defined dose. Neither approach has human data beyond the 1990s studies.
- Half-life and dose splitting: human half-life is about 2.1 hours (Aksenov 1996), so twice-daily split dosing gives more even exposure than one dose.
- Time of day: no data; morning and early-afternoon dosing is common practice for this activating class, given bemitil’s sleep-shortening effects noted in a review (Oliynyk 2012).
- Genetic polymorphisms: no pharmacogenetic data exist; no gene variant is known to require a dose change.
- Sex: no sex-specific dosing data; the poisoning study dosed men and women identically (Aksenov 1996).
- Age: no data in adults over 60; the once-daily schedule was used only in severe poisoning, where elimination slowed (Aksenov 1996); whether age-related slower clearance calls for a similar change is untested.
- Baseline biomarkers: a review links low or average resistance to extreme conditions to greater response (Oliynyk 2012); abnormal liver or kidney values would slow clearance and argue for lower frequency.
- Pre-existing conditions: acute poisoning prolonged half-life to 7.8–9.0 hours (Aksenov 1996); liver or kidney disease would likely do the same.
Discontinuation & Cycling
- Short-term only: human and animal efficacy regimens lasted 3–13 days (Aksenov 1996, Zarubina 2005); long-term use is unstudied, and rat toxicity appeared beyond one week (Pitkevich 2012).
- Withdrawal effects: none have been described in any human or animal source.
- Tapering: no tapering protocol exists; given the 2-hour half-life, courses simply end.
- Cycling: short courses with drug-free breaks are the class pattern, e.g., bemitil in three 5-day courses separated by 2-day breaks (Okovity 2005); no etomerzol cycling data exist.
- Efficacy over time: whether etomerzol’s effect fades with repetition is unknown; a review reports that bemitil’s effect builds over 3–5 days and then plateaus (Oliynyk 2012).
Sourcing and Quality
- No approved product: a review lists only bemitil and bromantane as permitted actoprotectors (Oliynyk 2012); a 2012 Belarusian report used an injectable ampoule form (Pitkevich 2012), but no current pharmaceutical supplier was found.
- Research-chemical supply: vendors sell milligram packages labeled for research only, not human use, e.g., the Smolecule product page listing ≥98% purity; purity claims are self-reported.
- Identity verification: the vendor lists CAS (Chemical Abstracts Service registry) number 120764-43-4 (Smolecule product page); an independent certificate of analysis using HPLC (high-performance liquid chromatography, a purity test) and mass spectrometry (molecular-weight analysis) is the only identity check.
- Salt form: studied material was the hydrochloride salt (Sergeeva 2008); free base (the non-salt form) and salt differ in weight and solubility, so doses do not transfer one-to-one.
- Sterility: research powders are neither sterile nor tested for fever-causing contaminants; a review reports the original solution was strongly acidic (Oliynyk 2012).
- Third-party testing and brands: no ConsumerLab, USP (U.S. Pharmacopeia) or NSF (NSF International, a certification body) testing exists, and no reputable brand or compounding pharmacy supplies etomerzol.
Practical Considerations
- Time to effect: volunteers showed effects within single 6–24-hour exertion sessions; in poisoned patients, recovery differences emerged from day 3–5 (Aksenov 1996).
- Regulatory status: a review reports that clinical development stopped in 1991 and that only bemitil and bromantane in this class reached permitted medical use (Oliynyk 2012); etomerzol is therefore an unapproved investigational compound with no prescribing information.
- Cost and access: the cited supplier sells only 5–10 mg research packages (Smolecule product page), far below the 80 mg clinical dose. No insurer or health system covers it, so payer incentives do not shape its evidence base.
- Common pitfalls: extrapolating bemitil data to etomerzol, converting rat mg/kg doses directly to humans, injecting non-sterile powder, and extending use beyond the 7–10 days where rat toxicity appeared.
- Language and source concentration: nearly all literature is Russian and comes largely from the Military Medical Academy group that developed benzimidazole actoprotectors; English abstracts often omit methods and numbers.
Interaction with Foundational Habits
- Sleep: Possibly blunting; untested for etomerzol. A review reports that bemitil can shorten and lighten sleep through psychoactivation (Oliynyk 2012), and rats on etomerzol showed more exploratory activity (Zavarina 2023). Morning dosing is the usual practical response.
- Nutrition: Indirect. A review reports that bemitil absorbs faster with carbohydrate-rich meals and works partly through glucose rebuilding in the liver (Oliynyk 2012), so adequate carbohydrate intake is relevant; fasting or very-low-carbohydrate states add theoretical hypoglycemia risk. No nutrient depletion is documented.
- Exercise: Potentiating for endurance during 6–24-hour loads in volunteers (Aksenov 1996). Its antioxidant action could theoretically blunt training adaptation, as vitamins C and E did for exercise-induced insulin-sensitivity gains (Ristow 2009); untested with training.
- Stress management: Possibly potentiating. A review frames actoprotectors as raising tolerance of physical and toxic stress (Oliynyk 2012), and etomerzol produced anxiety-reducing behavior in rats after stroke (Zavarina 2023); effects on cortisol (the main stress hormone) are unstudied.
Monitoring Protocol & Defining Success
Baseline testing: Before any exposure, a liver panel, kidney function test and complete blood count establish reference values, because the only repeated-dose study found liver, kidney and platelet changes in rats (Pitkevich 2012). A resting blood-pressure reading and a simple endurance benchmark, such as a timed run or ride, complete the baseline.
Ongoing monitoring: Laboratory tests are repeated at day 7 and at the end of a course, then 2–4 weeks after stopping if any value changed. Blood pressure is checked daily during the first 3 days. Success is defined by improvement on the personal endurance benchmark without laboratory change; no validated marker of etomerzol benefit exists.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| ALT | 7–56 U/L (standard reference range) | Safety check: rise signals the liver injury seen in rats; a value above 3× the upper limit is the stopping threshold | Ranges vary by laboratory; no fasting needed; pair with AST and bilirubin |
| AST | 10–40 U/L (standard reference range) | Safety check: liver injury | Also rises after hard exercise; strenuous training in the 48 hours before testing can raise the value |
| Total bilirubin | 0.1–1.2 mg/dL (standard reference range) | Safety check: liver processing function | Fasting improves accuracy; Gilbert syndrome (benign inherited bilirubin elevation) raises baseline |
| Creatinine | 0.7–1.3 mg/dL men, 0.6–1.1 mg/dL women (standard reference range) | Safety check: kidney-tubule damage seen in rats | Report with eGFR (estimated glomerular filtration rate, a kidney-filtration estimate); high muscle mass or creatine supplements raise values |
| Platelet count | 150–450 ×10⁹/L (standard reference range) | Safety check: platelet swings in rats and bleeding risk | Part of complete blood count; a value below 100 ×10⁹/L is the stopping threshold |
| Blood pressure | No established target; track change from own baseline | Safety check: hypotension from calcium-channel blockade | Seated, morning, before dosing; dizziness on standing is recorded alongside |
Qualitative markers:
- Injection-site pain, redness or hardening (if injected)
- Perceived exertion and recovery after long efforts
- Sleep onset and duration
- Dizziness on standing
- Unusual bruising or gum bleeding
Emerging Research
- Registered trials: a ClinicalTrials.gov search (October 2026) for all spellings and the actoprotector class found no registered etomerzol trial, completed or ongoing, so no trial result is expected to change this review’s evidence picture.
- Stroke neuroprotection: a 2023 rat study found larger early neurological-deficit reductions than bemitil (Zavarina 2023); replication by other groups would strengthen the case, while failure in other stroke models would weaken it.
- Repeated-dose safety: the only chronic study found organ damage from week two in rats (Pitkevich 2012); formal toxicology, including oral dosing, could confirm a narrow safety window or show oral use is better tolerated.
- Metabolism mapping: methods that charted bemitil’s metabolites (Belinskaia 2021) and its human urinary glucuronide (water-soluble conjugate) (Kwiatkowska 2018) could be applied to etomerzol, turning inferred interaction risks into measured ones.
- Human performance data: no controlled human endurance study of etomerzol has been published since the 1990s, and a review reports that clinical work stopped in 1991 (Oliynyk 2012); a positive placebo-controlled trial would upgrade the endurance claim, while a null result would leave only animal support.
Conclusion
Etomerzol is a Soviet-era synthetic compound designed as an injectable relative of bemitil, meant to help the body cope with heavy exertion, oxygen shortage and poisoning. For health-focused adults interested in resilience and recovery, its appeal lies in that design goal rather than in any shown effect on aging.
The evidence base is thin and old. The only human data on benefit come from a small study in poisoned patients and a volunteer endurance study, both run by the research group behind the drug program that produced the compound and reported mainly in a thesis summary. They point toward faster recovery and better endurance under extreme strain, but no independent group has repeated them. Everything else — brain protection, liver repair, better tolerance of low oxygen, protection against cell damage — rests on rat and cat experiments.
The picture of harms is equally incomplete. The original injectable form caused painful and sometimes destructive reactions where it was injected, and the only repeated-dose animal study found liver and kidney damage after about two weeks, along with swings in blood-clotting cells. How the body breaks the compound down, what it interacts with, and whether it is safe when swallowed are unknown. No approved product exists, so current use relies on research-grade powder of unchecked purity.
Taken together, etomerzol remains an experimental compound whose promise comes from animal work and its developers’ early clinical impressions, while its long-term safety and value for healthy adults are unknown.